Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CORCEPT THERAPEUTICS INCCORT · Entity 2620 | Director | May 21, 2026 | May 26, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CORCEPT THERAPEUTICS INC
Report date May 21, 2026 · Filed May 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right To Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $59.69 · Expires 2036-05-21 | Direct | 12,500 |
Reported balance
After 2026-05-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-21 · Grant · Acquired 12,500 · Balance 12,500 F1: Exercisable ratably in equal installments on each monthly anniversary of May 21, 2026 over a one-year period, subject to the Reporting Person's continued service on each monthly vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Exercisable ratably in equal installments on each monthly anniversary of May 21, 2026 over a one-year period, subject to the Reporting Person's continued service on each monthly vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 28, 2020 Filed Sep 2, 2020 00:26 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | PurchaseCommon Stock | 20,444 | $12.48 | $255,212.67 |
DisclosureSEC source: 0001225208-20-011150 · doc4.xml · nonDerivative · entry 1 BAKER G LEONARD JR · CIK 0001201715 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Ltd Partnership Disclosed balance after: 3,135,237 F1 · kind: The purchases reported in this Form 4 were matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, with the sales of shares by the reporting person, to the extent of the reporting person's pecuniary interest therein, at prices ranging from $15.76 to $15.7602, inclusive, on May 28, 2020. The reporting person has agreed to pay to the Issuer the profit realized by the reporting person in connection with the short-swing transaction, less transaction costs. F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.43 to $12.50, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F3 · ownership.nature: Shares held by a limited partnership of which the reporting person is a trustee of a trust which is the general partner. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein. Read SEC document |
| May 28, 2020 Filed May 29, 2020 20:09 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock Option (Right To Buy) · Derivative | 30,000 | $0.00 Strike: $3.47 | $0.00 |
DisclosureSEC source: 0001225208-20-008345 · doc4.xml · derivative · entry 6 BAKER G LEONARD JR · CIK 0001201715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2020-06-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Exercisable date is 6/23/2010 F1 · ownership.direct: The reporting person shares pecuniary interest in these shares with other individuals pursuant to a contractual relationship. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in these shares. Read SEC document |
| May 28, 2020 Filed May 29, 2020 20:09 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 30,000 | $15.70 | $471,060.00 |
DisclosureSEC source: 0001225208-20-008345 · doc4.xml · nonDerivative · entry 2 BAKER G LEONARD JR · CIK 0001201715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 996,838 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $15.69 to $15.7602, inclusive. The reporting person undertakes to provide to Corcept Therapeutics Incorporated, and any security holder of Corcept Therapeutics Incorporated, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1 · ownership.direct: The reporting person shares pecuniary interest in these shares with other individuals pursuant to a contractual relationship. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in these shares. Read SEC document |
| May 28, 2020 Filed May 29, 2020 20:09 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 30,000 | $3.47 | $104,100.00 |
DisclosureSEC source: 0001225208-20-008345 · doc4.xml · nonDerivative · entry 1 BAKER G LEONARD JR · CIK 0001201715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,026,838 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.direct: The reporting person shares pecuniary interest in these shares with other individuals pursuant to a contractual relationship. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in these shares. Read SEC document |
| May 27, 2020 Filed May 29, 2020 20:09 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantStock Option (Right To Buy) · Derivative | 30,000 | $0.00 Strike: $15.15 | $0.00 |
DisclosureSEC source: 0001225208-20-008345 · doc4.xml · derivative · entry 5 BAKER G LEONARD JR · CIK 0001201715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2030-05-27 F5 · derivative.exercise_date: Exercisable ratably in equal installments on each monthly anniversary of May 27, 2020 over one-year period. Read SEC document |
| January 01, 2020 Filed Feb 3, 2021 22:39 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GiftCommon Stock | 0 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-001608 · doc5.xml · nonDerivative · entry 1 BAKER G LEONARD JR · CIK 0001201715 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Ltd Partnership Disclosed balance after: 3,114,793 F1 · kind: Represents gift of limited partnership interests in a limited partnership to other limited partners. The reporting person disclaims beneficial ownership of the shares held by the limited partnership except as to the reporting person's pecuniary interest therein. F1 · price: Represents gift of limited partnership interests in a limited partnership to other limited partners. The reporting person disclaims beneficial ownership of the shares held by the limited partnership except as to the reporting person's pecuniary interest therein. F2 · ownership.nature: Shares held by a limited partnership of which the reporting person is a trustee of a trust which is the general partner. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein. Read SEC document |
| June 18, 2019 Filed Jun 19, 2019 23:19 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantStock Option (Right To Buy) · Derivative | 25,000 | $0.00 Strike: $10.50 | $0.00 |
DisclosureSEC source: 0001225208-19-009444 · doc4.xml · derivative · entry 1 BAKER G LEONARD JR · CIK 0001201715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2019-06-18 F1 · derivative.exercise_date: Exercisable ratably in equal installments on each monthly anniversary of June 18, 2019 over one-year period. Read SEC document |
| June 03, 2019 Filed Jun 5, 2019 20:24 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock Option (Right To Buy) · Derivative | 30,000 | $0.00 Strike: $0.96 | $0.00 |
DisclosureSEC source: 0001225208-19-008891 · doc4.xml · derivative · entry 5 BAKER G LEONARD JR · CIK 0001201715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2019-06-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.direct: The reporting person shares pecuniary interest in these shares with other individuals pursuant to a contractual relationship. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in these shares. Read SEC document |
| June 03, 2019 Filed Jun 5, 2019 20:24 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 30,000 | $9.78 | $293,298.00 |
DisclosureSEC source: 0001225208-19-008891 · doc4.xml · nonDerivative · entry 2 BAKER G LEONARD JR · CIK 0001201715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 996,838 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $9.75 to $9.80, inclusive. The reporting person undertakes to provide to Corcept Therapeutics Incorporated, and any security holder of Corcept Therapeutics Incorporated, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1 · ownership.direct: The reporting person shares pecuniary interest in these shares with other individuals pursuant to a contractual relationship. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in these shares. Read SEC document |
| June 03, 2019 Filed Jun 5, 2019 20:24 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 30,000 | $0.96 | $28,800.00 |
DisclosureSEC source: 0001225208-19-008891 · doc4.xml · nonDerivative · entry 1 BAKER G LEONARD JR · CIK 0001201715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,026,838 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.direct: The reporting person shares pecuniary interest in these shares with other individuals pursuant to a contractual relationship. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in these shares. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 21:34 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | PurchaseCommon Stock | 70,000 | $11.39 | $797,097.00 |
DisclosureSEC source: 0001225208-19-002545 · doc4.xml · nonDerivative · entry 2 BAKER G LEONARD JR · CIK 0001201715 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Ltd Partnership Disclosed balance after: 3,114,793 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.30 to $11.50, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: Shares held by a limited partnership of which the reporting person is a trustee of a trust which is the general partner. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 21:34 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | PurchaseCommon Stock | 30,000 | $11.39 | $341,613.00 |
DisclosureSEC source: 0001225208-19-002545 · doc4.xml · nonDerivative · entry 1 BAKER G LEONARD JR · CIK 0001201715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 996,838 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.30 to $11.50, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| January 01, 2019 Filed Mar 5, 2020 22:59 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GiftCommon Stock | 0 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-004449 · doc5.xml · nonDerivative · entry 1 BAKER G LEONARD JR · CIK 0001201715 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Ltd Partnership Disclosed balance after: 3,044,793 F1 · kind: Represents gift of limited partnership interests in a limited partnership to other limited partners. The reporting person disclaims beneficial ownership of the shares held by the limited partnership except as to the reporting person's pecuniary interest therein. F1 · price: Represents gift of limited partnership interests in a limited partnership to other limited partners. The reporting person disclaims beneficial ownership of the shares held by the limited partnership except as to the reporting person's pecuniary interest therein. F2 · ownership.nature: Shares held by a limited partnership of which the reporting person is a trustee of a trust which is the general partner. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein. Read SEC document |
| November 21, 2018 Filed Nov 26, 2018 22:13 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | PurchaseCommon Stock | 70,000 | $12.73 | $890,785.00 |
DisclosureSEC source: 0001225208-18-015870 · doc4.xml · nonDerivative · entry 2 BAKER G LEONARD JR · CIK 0001201715 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Ltd Partnership Disclosed balance after: 3,044,793 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.29 to $12.91, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: Shares held by a limited partnership of which the reporting person is a trustee of a trust which is the general partner. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein. Read SEC document |
| November 21, 2018 Filed Nov 26, 2018 22:13 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | PurchaseCommon Stock | 30,000 | $12.73 | $381,765.00 |
DisclosureSEC source: 0001225208-18-015870 · doc4.xml · nonDerivative · entry 1 BAKER G LEONARD JR · CIK 0001201715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 966,838 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.29 to $12.91, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| November 13, 2018 Filed Nov 14, 2018 22:26 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | PurchaseCommon Stock | 25,420 | $12.87 | $327,104.56 |
DisclosureSEC source: 0001225208-18-015527 · doc4.xml · nonDerivative · entry 6 BAKER G LEONARD JR · CIK 0001201715 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Ltd Partnership Disclosed balance after: 2,974,793 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.75 to $13.00, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F4 · ownership.nature: Shares held by a limited partnership of which the reporting person is a trustee of a trust which is the general partner. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein. Read SEC document |
| November 13, 2018 Filed Nov 14, 2018 22:26 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | PurchaseCommon Stock | 10,895 | $12.87 | $140,196.86 |
DisclosureSEC source: 0001225208-18-015527 · doc4.xml · nonDerivative · entry 3 BAKER G LEONARD JR · CIK 0001201715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 936,838 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.75 to $13.00, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| November 12, 2018 Filed Nov 14, 2018 22:26 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | PurchaseCommon Stock | 73,914 | $12.94 | $956,698.47 |
DisclosureSEC source: 0001225208-18-015527 · doc4.xml · nonDerivative · entry 5 BAKER G LEONARD JR · CIK 0001201715 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Ltd Partnership Disclosed balance after: 2,949,373 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.72 to $13.00, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F4 · ownership.nature: Shares held by a limited partnership of which the reporting person is a trustee of a trust which is the general partner. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein. Read SEC document |
| November 12, 2018 Filed Nov 14, 2018 22:26 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | PurchaseCommon Stock | 31,677 | $12.94 | $410,008.08 |
DisclosureSEC source: 0001225208-18-015527 · doc4.xml · nonDerivative · entry 2 BAKER G LEONARD JR · CIK 0001201715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 925,943 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.72 to $13.00, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| November 09, 2018 Filed Nov 14, 2018 22:26 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | PurchaseCommon Stock | 40,666 | $13.00 | $528,658.00 |
DisclosureSEC source: 0001225208-18-015527 · doc4.xml · nonDerivative · entry 4 BAKER G LEONARD JR · CIK 0001201715 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Ltd Partnership Disclosed balance after: 2,875,459 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.99 to $13.00, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F4 · ownership.nature: Shares held by a limited partnership of which the reporting person is a trustee of a trust which is the general partner. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein. Read SEC document |
| November 09, 2018 Filed Nov 14, 2018 22:26 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | PurchaseCommon Stock | 17,428 | $13.00 | $226,564.00 |
DisclosureSEC source: 0001225208-18-015527 · doc4.xml · nonDerivative · entry 1 BAKER G LEONARD JR · CIK 0001201715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 894,266 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.99 to $13.00, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| August 20, 2018 Filed Aug 22, 2018 21:54 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantStock Option (Right To Buy) · Derivative | 25,000 | $0.00 Strike: $14.08 | $0.00 |
DisclosureSEC source: 0001225208-18-012868 · doc4.xml · derivative · entry 4 BAKER G LEONARD JR · CIK 0001201715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2028-08-20 F4 · derivative.exercise_date: Exercisable ratably in equal installments on each monthly anniversary of May 29, 2018 over a one-year period. Read SEC document |
| August 20, 2018 Filed Aug 22, 2018 21:54 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | PurchaseCommon Stock | 35,681 | $12.92 | $461,094.86 |
DisclosureSEC source: 0001225208-18-012868 · doc4.xml · nonDerivative · entry 1 BAKER G LEONARD JR · CIK 0001201715 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Ltd Partnership Disclosed balance after: 2,834,793 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.789 to $13.00, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: Shares held by a limited partnership of which the reporting person is a trustee of a trust which is the general partner. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein. Read SEC document |
| August 17, 2018 Filed Aug 20, 2018 22:19 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | PurchaseCommon Stock | 5,792 | $12.80 | $74,117.33 |
DisclosureSEC source: 0001225208-18-012759 · doc4.xml · nonDerivative · entry 2 BAKER G LEONARD JR · CIK 0001201715 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Ltd Partnership Disclosed balance after: 2,799,112 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.60 to $12.80, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: Shares held by a limited partnership of which the reporting person is a trustee of a trust which is the general partner. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein. Read SEC document |
| August 16, 2018 Filed Aug 20, 2018 22:19 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | PurchaseCommon Stock | 100,000 | $12.49 | $1,248,760.00 |
DisclosureSEC source: 0001225208-18-012759 · doc4.xml · nonDerivative · entry 1 BAKER G LEONARD JR · CIK 0001201715 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Ltd Partnership Disclosed balance after: 2,793,320 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.315 to $12.60, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: Shares held by a limited partnership of which the reporting person is a trustee of a trust which is the general partner. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein. Read SEC document |
| August 15, 2018 Filed Aug 16, 2018 21:51 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | PurchaseCommon Stock | 79,686 | $12.49 | $994,967.36 |
DisclosureSEC source: 0001225208-18-012682 · doc4.xml · nonDerivative · entry 2 BAKER G LEONARD JR · CIK 0001201715 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Ltd Partnership Disclosed balance after: 2,693,320 F1 · kind: The purchases reported in this Form 4 were matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, with the sales of shares by the reporting person, to the extent of the reporting person's pecuniary interest therein, at prices ranging from $16.00 to $16.22, inclusive, on May 11, 2018. The reporting person has paid to the Issuer the profit realized by the reporting person in connection with the short-swing transaction, less transaction costs. F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.25 to $12.50, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. The reporting person has paid to the issuer the profit realized by the reporting person in connection with the short-swing transaction, less transaction costs. F4 · ownership.nature: Shares held by a limited partnership of which the reporting person is a trustee of a trust which is the general partner. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein. Read SEC document |
| August 14, 2018 Filed Aug 16, 2018 21:51 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | PurchaseCommon Stock | 100,000 | $12.47 | $1,247,000.00 |
DisclosureSEC source: 0001225208-18-012682 · doc4.xml · nonDerivative · entry 1 BAKER G LEONARD JR · CIK 0001201715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 876,838 F1 · kind: The purchases reported in this Form 4 were matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, with the sales of shares by the reporting person, to the extent of the reporting person's pecuniary interest therein, at prices ranging from $16.00 to $16.22, inclusive, on May 11, 2018. The reporting person has paid to the Issuer the profit realized by the reporting person in connection with the short-swing transaction, less transaction costs. F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.40 to $12.50, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| May 11, 2018 Filed May 15, 2018 21:30 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock Option (Right To Buy) · Derivative | 30,000 | $0.00 Strike: $2.23 | $0.00 |
DisclosureSEC source: 0001225208-18-009351 · doc4.xml · derivative · entry 5 BAKER G LEONARD JR · CIK 0001201715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2018-06-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.direct: The reporting person shares pecuniary interest in these shares with other individuals pursuant to a contractual relationship. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in these shares. Read SEC document |
| May 11, 2018 Filed May 15, 2018 21:30 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 30,000 | $16.01 | $480,312.00 |
DisclosureSEC source: 0001225208-18-009351 · doc4.xml · nonDerivative · entry 2 BAKER G LEONARD JR · CIK 0001201715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 776,838 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $16.00 to $16.22, inclusive. The reporting person undertakes to provide to Corcept Therapeutics Incorporated, and any security holder of Corcept Therapeutics Incorporated, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1 · ownership.direct: The reporting person shares pecuniary interest in these shares with other individuals pursuant to a contractual relationship. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in these shares. Read SEC document |
| May 11, 2018 Filed May 15, 2018 21:30 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 30,000 | $2.23 | $66,900.00 |
DisclosureSEC source: 0001225208-18-009351 · doc4.xml · nonDerivative · entry 1 BAKER G LEONARD JR · CIK 0001201715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 806,838 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.direct: The reporting person shares pecuniary interest in these shares with other individuals pursuant to a contractual relationship. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in these shares. Read SEC document |
| January 01, 2018 Filed Feb 12, 2019 00:07 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GiftCommon Stock | 0 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-002197 · doc5.xml · nonDerivative · entry 1 BAKER G LEONARD JR · CIK 0001201715 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Ltd Partnership Disclosed balance after: 3,044,793 F1 · kind: Represents gift of limited partnership interests in a limited partnership to other limited partners. The reporting person disclaims beneficial ownership of the shares held by the limited partnership except as to the reporting person's pecuniary interest therein. F1 · price: Represents gift of limited partnership interests in a limited partnership to other limited partners. The reporting person disclaims beneficial ownership of the shares held by the limited partnership except as to the reporting person's pecuniary interest therein. F2 · ownership.nature: Shares held by a limited partnership of which the reporting person is a trustee of a trust which is the general partner. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein. Read SEC document |
| November 13, 2017 Filed Nov 15, 2017 22:27 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock Option (Right To Buy) · Derivative | 30,000 | $0.00 Strike: $2.70 | $0.00 |
DisclosureSEC source: 0001225208-17-017372 · doc4.xml · derivative · entry 5 BAKER G LEONARD JR · CIK 0001201715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2017-12-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.direct: The reporting person shares pecuniary interest in these shares with other individuals pursuant to a contractual relationship. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in these shares. Read SEC document |
| November 13, 2017 Filed Nov 15, 2017 22:27 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 30,000 | $17.59 | $527,556.00 |
DisclosureSEC source: 0001225208-17-017372 · doc4.xml · nonDerivative · entry 2 BAKER G LEONARD JR · CIK 0001201715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 776,838 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $17.55 to $17.65, inclusive. The reporting person undertakes to provide to Corcept Therapeutics Incorporated, and any security holder of Corcept Therapeutics Incorporated, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1 · ownership.direct: The reporting person shares pecuniary interest in these shares with other individuals pursuant to a contractual relationship. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in these shares. Read SEC document |
| November 13, 2017 Filed Nov 15, 2017 22:27 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 30,000 | $2.70 | $81,000.00 |
DisclosureSEC source: 0001225208-17-017372 · doc4.xml · nonDerivative · entry 1 BAKER G LEONARD JR · CIK 0001201715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 806,838 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.direct: The reporting person shares pecuniary interest in these shares with other individuals pursuant to a contractual relationship. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in these shares. Read SEC document |
| May 24, 2017 Filed May 26, 2017 21:29 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantStock Option (Right To Buy) · Derivative | 30,000 | $0.00 Strike: $12.13 | $0.00 |
DisclosureSEC source: 0001225208-17-010499 · doc4.xml · derivative · entry 1 BAKER G LEONARD JR · CIK 0001201715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2027-05-24 F1 · derivative.exercise_date: Exercisable ratably in equal installments on each monthly anniversary of May 24, 2017 over one-year period. Read SEC document |
| January 01, 2017 Filed Feb 14, 2018 00:33 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GiftCommon Stock | 0 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-002815 · doc5.xml · nonDerivative · entry 1 BAKER G LEONARD JR · CIK 0001201715 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Ltd Partnership Disclosed balance after: 2,613,634 F1 · kind: Represents gift of limited partnership interests in a limited partnership to other limited partners. The reporting person disclaims beneficial ownership of the shares held by the limited partnership except as to the reporting person's pecuniary interest therein. F2 · ownership.nature: Shares held by a limited partnership of which the reporting person is a trustee of a trust which is the general partner. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein. Read SEC document |
| September 30, 2016 Filed Feb 13, 2017 21:59 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GiftCommon Stock | 0 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-003004 · doc5.xml · nonDerivative · entry 2 BAKER G LEONARD JR · CIK 0001201715 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Ltd Partnership Disclosed balance after: 2,613,634 F1 · kind: Represents gift of limited partnership interests in a limited partnership to other limited partners. The reporting person disclaims beneficial ownership of the shares held by the limited partnership except as to the reporting person's pecuniary interest therein. F2 · ownership.nature: Shares held by a limited partnership of which the reporting person is a trustee of a trust which is the General Partner. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein. Read SEC document |
| January 01, 2016 Filed Feb 13, 2017 21:59 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GiftCommon Stock | 0 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-003004 · doc5.xml · nonDerivative · entry 1 BAKER G LEONARD JR · CIK 0001201715 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Ltd Partnership Disclosed balance after: 2,613,634 F1 · kind: Represents gift of limited partnership interests in a limited partnership to other limited partners. The reporting person disclaims beneficial ownership of the shares held by the limited partnership except as to the reporting person's pecuniary interest therein. F2 · ownership.nature: Shares held by a limited partnership of which the reporting person is a trustee of a trust which is the General Partner. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.